Capital One analyst Zegbeh Jallah remains a buyer of Ideaya Biosciences after the company announced the initiation of a Phase 2 clinical study of darovasertib in the neoadjuvant and adjuvant uveal melanoma settings. The analyst says that while neoadjuvant or adjuvant use is not yet a part of the firm’s $29 price target valuation, it offers "major upside given the large market opportunity." Ideaya’s "rapid progress" has made Capital One more bullish on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences price target raised to $26 from $22 at Oppenheimer
- Ideaya Biosciences provides update on darovasertib trials
- Oppenheimer feels ‘a lot better’ about Ideaya’s darovasertib plan after talks
- Ideaya upside ‘even more likely’ after IND accepted, says Capital One
- Ideaya Biosciences announces FDA conclusion that its IDE161 trial may proceed